These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 21942930)

  • 21. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
    Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
    Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
    Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
    Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of eculizumab in renal transplantation.
    Barnett AN; Asgari E; Chowdhury P; Sacks SH; Dorling A; Mamode N
    Clin Transplant; 2013; 27(3):E216-29. PubMed ID: 23516966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.
    Chehade H; Rotman S; Matter M; Girardin E; Aubert V; Pascual M
    Pediatrics; 2015 Feb; 135(2):e551-5. PubMed ID: 25624380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients.
    Patel JK; Coutance G; Loupy A; Dilibero D; Hamilton M; Kittleson M; Kransdorf E; Azarbal B; Seguchi O; Zhang X; Chang D; Geft D; Czer L; Varnous S; Kobashigawa JA
    Am J Transplant; 2021 Jul; 21(7):2479-2488. PubMed ID: 33251691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
    Kuppachi S; Holanda D; Gallegos S; Field EH
    Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats.
    Tajima T; Hata K; Kusakabe J; Miyauchi H; Badshah JS; Kageyama S; Zhao X; Kim SK; Tsuruyama T; Kirchner VA; Watanabe T; Uemoto S; Hatano E
    Front Immunol; 2023; 14():1186653. PubMed ID: 37398677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electron-dense deposit in renal transplant patients on eculizumab may be drug-derived.
    Brealey JK; Cassidy J
    Ultrastruct Pathol; 2016; 40(1):2-6. PubMed ID: 26512451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year.
    Cornell LD; Schinstock CA; Gandhi MJ; Kremers WK; Stegall MD
    Am J Transplant; 2015 May; 15(5):1293-302. PubMed ID: 25731800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal allograft pathology in the sensitized patient.
    Cornell LD
    Curr Opin Organ Transplant; 2013 Jun; 18(3):327-36. PubMed ID: 23619513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.